Medical Equipment

Clinical Oncology Next Generation Sequencing Market Analysis 2025–2029: Growth Forecast and Competitive Insights

December 8, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the clinical oncology next generation sequencing market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Clinical Oncology Next Generation Sequencing Market Be Worth By 2029, And What CAGR Will It Achieve?

The clinical oncology next generation sequencing market size has seen rapid expansion in recent years. It is anticipated to grow from $0.51 billion in 2024 to $0.58 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.9%. The market’s historical growth can be attributed to advances in genomic research, the discovery of cancer biomarkers, continuous technological improvements, and successful regulatory approvals.

The clinical oncology next generation sequencing market is projected for significant expansion in the coming years. This market is anticipated to reach $0.94 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.7%. Factors contributing to this projected growth include the increasing incidence of cancer, advancements in precision medicine, the rise of immuno-oncology, and the adoption of liquid biopsies. Key developments expected during this period encompass comprehensive genomic profiling (cgp), continued advancements in immuno-oncology, a focus on tumor evolution and heterogeneity, and the integration of AI and machine learning.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Which Factors Are Driving The Clinical Oncology Next Generation Sequencing Market Forward?

The global increase in cancer cases is expected to fuel the expansion of the clinical oncology next-generation sequencing market throughout the forecast period. For instance, in May 2024, the National Cancer Institute, a US-based government agency, reported approximately 18.1 million cancer survivors in the United States. This figure is projected to rise to 22.5 million by 2032. By 2040, the number of new cancer cases each year is anticipated to reach 29.9 million, with cancer-related deaths estimated to climb to 15.3 million. Therefore, the escalating global cancer incidence rate is foreseen to significantly boost the demand for the growth of the clinical oncology next-generation sequencing market.

Which Segments Form The Key Structure Of The Clinical Oncology Next Generation Sequencing Market?

The clinical oncology next generation sequencingmarket covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

How Are Global Trends Impacting The Development Of The Clinical Oncology Next Generation Sequencing Market?

Major companies in the clinical oncology next-generation sequencing market are developing new products, such as the BenchMark ULTRA PLUS system, to boost their profitability. The BenchMark ULTRA PLUS System is a vital tool for clinical laboratories, particularly those involved in cancer diagnostics and research, as it ensures the accuracy and efficiency of diagnostic tests, thereby contributing to improved patient care. For instance, in June 2022, Roche, a Switzerland-based pharmaceutical company, launched the BenchMark ULTRA PLUS system, which is its most advanced platform for tissue staining. This system delivers quick and precise test results, aiding clinicians in making timely decisions about a patient’s course of therapy.

Which Firms Are Making The Biggest Impact In The Clinical Oncology Next Generation Sequencing Market?

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

Which Region Is Expected To Lead The Clinical Oncology Next Generation Sequencing Market In The Next Few Years?

North America was the largest region in the clinical oncology next-generation sequencing market in 2024. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

Browse Through More Reports Similar to the Global Clinical Oncology Next Generation Sequencing Market 2025, By The Business Research Company

Synthetic Biology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/synthetic-biology-global-market-report

Molecular Diagnostics Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-devices-and-equipment-global-market-report

Molecular Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/molecular-diagnostics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795